Sonic Healthcare (SHL) H2 2024 earnings summary

Executive summary

• FY 2024 marked a transition from pandemic disruption to normalized operations, with total revenue rising 10% to A$8,967 million and strong financial and market positioning maintained.

• Organic revenue growth remained robust at 6%, underpinned by medical leadership and strategic M&A activity in Germany, Switzerland, USA, and the UK.

• Post-pandemic headcount reduction program is largely complete, optimizing cost structure for future growth.

• Net profit for FY 2024 was A$511 million, down 25% year-over-year due to lower COVID-19 testing revenues.

• Cash generation remained strong, with 95% EBITDA conversion to gross operating cash flow.

Financial highlights

• Total revenue for FY 2024 was just under A$9 billion; base business revenue grew 16% to A$8,905 million, while COVID-related revenue dropped to A$62 million.

• EBITDA (excluding one-time gains) was A$1,602 million, in line with guidance but down 6% year-over-year.

• EBITDA margin expanded in H2 FY 2024 compared to H1.

• Acquisitions contributed A$655 million in new annual revenue.

• Final dividend of A$0.63 per share (up 2%), total annual dividend A$1.06 per share (up 2%).

Outlook and guidance

• FY 2025 EBITDA guidance: A$1.7–1.75 billion (constant currency), reflecting up to 10% growth.

• Interest expense expected to rise 25% due to acquisitions; effective tax rate projected at 26–27%.

• Guidance includes A$15 million potential PAMA fee cuts in the USA and an initial A$10 million loss from a new UK contract, both with future profitability expected.

• July 2024 trading in line with budget.

• Management expects easing inflationary pressures and continued organic growth and margin improvement.